A. Vieillefond, P. Beuzeboc, L. Mignot, E. Banu, F. Priou, E. Malaurie, P. Dalivoust, X. Muracciole, M. Sibony and S. Oudard HER2 status in urothelial bladder cancer (UC): screening of patients eligible for a phase II randomized study of gemcitabine plus platinum salt with or without trastuzumab. Abstract 4700. J Clin Oncol (supplement) 2005;23(16S):427s., 2005.

A. Banu, S. Oudard, E. Banu, D. Kamioneur, M. Housset, N. Thiounn, F. Scotte, A. Jenabian, A. Mejean, J. M. Andrieu Combination of prostate-specific antigen (PSA) exposure and Gleason score as prognostic factors for prostate cancer (PC) patients. Poster presentation. Abstract 73. Proceedings of Prostate Cancer Symposium, 17 February, Orlando, Florida 2005:70., 2005.

S. Oudard, E. Banu, A. Banu, F. Scotte, E. Levy, J. Medioni, E. Fabre Guillevin, J. Ayllon, N. Arakelyan, J. M. Andrieu Docetaxel versus mitoxantrone as first-line chemotherapy for hormone-refractory prostate cancer (HRPC) patients. A meta-analysis of 3-year overall survival results. Poster presentation. Abstract 4634. J Clin Oncol (supplement) 2005;23(16S):411s., 2005.

E. Banu, S. Oudard, A. Banu, A. Fodor, B. Landi, T. Lecomte, P. Laurent-Puig, P. H. Cugnenc, J. M. Andrieu Cumulative meta-analysis of randomized trials comparing gemcitabine-based chemotherapy versus gemcitabine alone in patients with advanced or metastatic pancreatic cancer (PC). Poster presentation. Abstract 4101. J Clin Oncol (supplement) 2005;23(16S):333s., 2005.

E. Banu, M. Levee, F. Scotte, A. Banu, S. Oudard, J. Ayllon, C. Le Maignan, B. Bonan, A. L. Le Louet, J. M. Andrieu Corrected area under serum hemoglobin curve (Hb c-AUC) as a predictor of maximal hemoglobin response after erythropoietin (rHuEpo) treatment in chemotherapy induced anemia patients. Poster presentation. Abstract 9586. J Clin Oncol (supplement) 2004;22(14S):852., 2004.

A. Banu, D. Helley, E. Banu, A. M. Fischer, F. Scotte, A. Bouziane, S. Oudard Platelet microparticles (PMP): A predictive factor of overall survival in hormone-refractory prostate cancer (HRPC) patients treated by chemotherapy. Poster presentation. Abstract 4639. J Clin Oncol (supplement) 2006;24(18S):251s, 2006.

J. Ayllon, S. Oudard, E. Banu, J. L. Janneau, D. Helley, S. Richon, A. Banu, E. Levy, J. Medioni, D. Bellet Early placenta insuline-like peptide (pro-EPIL): A novel biomarker in advanced and metastatic non-small cell lung cancer (NSCLC) patients treated by chemotherapy. Abstract 20069. J Clin Oncol (supplement) 2006;24(18S):706s., 2006.

E. Banu, O. Rixe, C. Linassier, J. P. Machiels, M. Baudard, F. Ringeisen, T. Velu, M. A. Lefrere-Belda, J. M. Limacher, S. Oudard A phase II study of the cancer vaccine TG4010 alone and in combination with cytokines in patients with metastatic renal cell carcinoma (RCC). Poster presentation. Abstract 2581. J Clin Oncol (supplement) 2006;24(18S):120s., 2006.

S, Oudard S, Duclos B, Banu E, Priou F, Rousseau F, Langlois D, Banu A, Rolland F A phase II prospective study of gemcitabine and platinum-based combination as first-line chemotherapy for metastatic Bellini duct carcinoma patients. Results of GETUG study. Poster discussion. Abstract 4543. J Clin Oncol (supplement) 2005;23(16S):390s., 2005.

Scotte F, Banu E, Oudard S, Banu A, Medioni J, Fabre-Guillevin E, Mejean A, Fontaine E, Thiounn N, Andrieu JM Prostate-specific antigen doubling-time (PSA DT) before onset of chemotherapy as survival predictor for hormone refractory prostate cancer (HRPC) patients. Poster discussion. Abstract 4551. J Clin Oncol (supplement) 2005;23(16S):390s., 2005.

Rusu MC, Vasilescu A, Nimigean V. A rare anatomic variant: the lateral position of the external carotid artery.. Int J Oral Maxillofac Surg., p.1066-7, 2006.

Zhu G, Bartsch O, Skrypnyk C, Rotondo A, Akhtar LA, Harris C, Virkkunen M, Cassano G, Goldman D. „Failure to detect DUP25 in lymphoblastoid cells derived from patients with panic disorder and control individuals representing European and American populations”.. Eur J Hum Genet., p.505-8., 2004.

Skrypnyk C, Goecke TO, Majewski F, Bartsch O „Molecular cytogenetic characterization of a 10p14 deletion that includes the DGS2 region in a patient with multiple anomalies”.. Am J Med Genet, p.207-12, 2002.

Skrypnyk C, Bartsch O. • “Retinoblastoma, pinealoma, and mild overgrowth in a boy with a deletion of RB1 and neighbor genes on chromosome 13q14”.. Am J Med Genet., p.397-401, 2004.

Dospinescu C and Cruickshank SF Different role for [Cl-]o in hypoxia induced contractions of small intrapulmonary arteries and veins. J Mol Cell Cardiol, p.1015, 2006.

Zdrenghea, D, Banu, E, Bogdan, E, Beudean M The effect of low-dose amiodarone in prevention of paroxysmal atrial fibrillation. Rom J Intern Med, p.199-204, 1996.

Oudard S, Carpentier A, Banu E, Fauchon F, Celerier D, Poupon MF, Dutrillaux B, Andrieu JM, Delattre JY Phase II study of lonidamine and diazepam in the treatment of recurrent glioblastoma multiforme. Journal of Neurooncology, p.81-86, 2003.

Oudard S, Medioni J, Scotte F, Banu E Prostate cancer: update. Bulletin du Cancer, p.865-873, 2005.

Scotté F, Tourani JM, Banu E, Peyromaure M, Levy E, Marsan S, Magherini E, Fabre-Guillevin E, Andrieu JM, Oudard S Multicenter Study of a Frozen Glove to Prevent Docetaxel-Induced Onycholysis and Cutaneous Toxicity of the Hand. Journal of Clinical Oncology, p.4424-4429, 2005.

Oudard, S, Banu, E, Beuzeboc, P, Eric Voog, Louis Marie Dourthe, Anne Claire Hardy-Bessard, Claude Linassier, Florian Scotté, Adela Banu, Yvan Coscas, François Guinet, Marie-France Poupon, Jean-Marie Andrieu Multicenter Randomized Phase II Study of Two Schedules of Docetaxel, Estramustine, and Prednisone Versus Mitoxantrone Plus Prednisone in Patients With Metastatic Hormone-Refractory Prostate Cancer. Journal of Clinical Oncology, p.3343-3351, 2005.

Sarah Morgan, Jan Lubinski, Esra Manguoglu, Guven Luleci, Rebecca Doherty, Margaret Christie, Paul Craven, Elizabeth Bancroft, Anita Mitra, Karolina Zieba, Ros Eeles on behalf of the IMPACT steering committee and IMPACT collaborators IMPACT and AIDIT: Strengthening Research Ties in Eastern Europe. Hereditary Cancer in Clinical Practice, p.111-112, 2006.

V. Jinga, S. Persu, Lavinia G. Hinescu, A. Pociu, V. Voicu, M. Hinescu Cell death pattern after angiotensin receptor (AT1) blockade in developing and mature rat kidney. © 2002 BJU International 90(Suppl. 2), 201–207, p.201-207, 2002.

M.C. Ranetti, V. Istudor, A.E. Ranetti, Lavinia G. Hinescu, E. Ionica Plante cu actiune hipoglicemianta si principiile lor active. Farmacia, p.91-103, 2005.

Mihai Dupac, Sayavur Bakhtiyarov, Ruel A. Overfelt Volume Computation of a Levitated Aspherical Droplet From 2-D Image Information. Journal of Fluids Engineering, 2006.

C.Dumitrache Filaments Differential Rotation Behavior within the Solar Cycle. Romanian Astrophysical Journal, p.147, 2004.

Gorog Ilona Factori actuali de stres la personalul medical. Grupul Balint si ecologia institutiilor de sanatate. Buletinul Asociatiei Balint,, 2003.

Papapetropoulos A, Desai KM, Rudic RD, Mayer B, Zhang R, Ruiz-Torres MP, Garcia-Cardena G, Madri JA, Sessa WC Nitric oxide synthase inhibitors attenuate transforming-growth-factor-beta 1-stimulated capillary organization in vitro. Am J Pathol, p.1835-44, 1997.

Rudic RD, Shesely EG, Maeda N, Smithies O, Segal SS, Sessa WC Direct evidence for the importance of endothelium-derived nitric oxide in vascular remodeling. J Clin Invest, p.731-6, 1998.

Rudic RD, Sessa WC Nitric oxide in endothelial dysfunction and vascular remodeling: clinical correlates and experimental links. Am J Hum Genet, p.673-7, 1999.

Papapetropoulos A, Rudic RD, Sessa WC Molecular control of nitric oxide synthases in the cardiovascular system. Cardiovasc Res, p.509-20, 1999.

Rudic RD, Bucci M, Fulton D, Segal SS, Sessa WC Temporal events underlying arterial remodeling after chronic flow reduction in mice: correlation of structural changes with a deficit in basal nitric oxide synthesis. Circ Res, p.1160-6, 2000.

Luo Z, Fujio Y, Kureishi Y, Rudic RD, Daumerie G, Fulton D, Sessa WC, Walsh K Acute modulation of endothelial Akt/PKB activity alters nitric oxide-dependent vasomotor activity in vivo. J Clin Invest, p.493-9, 2000.

Bucci M, Gratton JP, Rudic RD, Acevedo L, Roviezzo F, Cirino G, Sessa WC In vivo delivery of the caveolin-1 scaffolding domain inhibits nitric oxide synthesis and reduces inflammation. Nat Med, p.1362-7, 2000.

Tereb DA, Kirkiles-Smith NC, Kim RW, Wang Y, Rudic RD, Schechner JS, Lorber MI, Bothwell AL, Pober JS, Tellides G Human T cells infiltrate and injure pig coronary artery grafts with activated but not quiescent endothelium in immunodeficient mouse hosts. Transplantation, p.1622-30, 2001.

McNamara P, Seo SP, Rudic RD, Sehgal A, Chakravarti D, FitzGerald GA Regulation of CLOCK and MOP4 by nuclear hormone receptors in the vasculature: a humoral mechanism to reset a peripheral clock. Cell, p.877-89, 2001.

Scotland RS, Morales-Ruiz M, Chen Y, Yu J, Rudic RD, Fulton D, Gratton JP, Sessa WC Functional reconstitution of endothelial nitric oxide synthase reveals the importance of serine 1179 in endothelium-dependent vasomotion. Circ Res, p.904-10, 2002.

Yu J, Rudic RD, Sessa WC Nitric oxide-releasing aspirin decreases vascular injury by reducing inflammation and promoting apoptosis. Lab Invest, p.825-32, 2002.

Curtis AM, Seo SB, Westgate EJ, Rudic RD, Smyth EM, Chakravarti D, FitzGerald GA, McNamara P Histone acetyltransferase-dependent chromatin remodeling and the vascular clock. J Biol Chem, p.7091-7, 2004.